<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132093">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382303</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-CT4-10-055</org_study_id>
    <nct_id>NCT01382303</nct_id>
  </id_info>
  <brief_title>Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients</brief_title>
  <official_title>Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients : Prospective, Randomized, Double Blinded Active Control, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized controlled study aims to evaluate the effects of
      pentoxifylline on proteinuria in Korean type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit adults patients with type 2 diabetes aged over 20 years with
      spot urine albumin to creatinine ratio over 30mg/g in two consecutive measurements.

      Enrolled patients will be randomly assigned to receive pentoxifylline (400mg three times
      daily) or placebo for 24 weeks.

      Fasting blood and spot urine will be collected at baseline, 12 weeks and 24 weeks.

      The investigators will evaluate the impact of pentoxifylline on proteinuria in type 2
      diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effects of pentoxifylline on proteinuria in type 2 diabetic patients</measure>
    <time_frame>every 12 weeks following radomization, for 24 weeks</time_frame>
    <description>Spont urine will be collected at baseline, 12 weeks and 24 weeks after randomization. Changes of urine protein to creatinie and urine albumin to creatinine ratio (mg/g) from baseline will be compared between the active group and placebo group. Estimated glomerular filtration rate (GFR) will be also calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of glucose control status markers</measure>
    <time_frame>every 12 weeks following randomization, for 24 weeks</time_frame>
    <description>Glucose control status markers such as fasting glucose (mg/dL), hemoglobin A1c (%), insulin (uU/mL) will be checked at baseline, 12 weeks and 24 weeks after randomization. The changes of above markers will be compared between the active group and placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of renal and liver function markers</measure>
    <time_frame>Every 12 weeks following randomization, for 24 weeks</time_frame>
    <description>Various markers that represent the function of kidney and liver will be checked at baseline, 12 weeks and 24 weeks after randomization. The markers are serum creatinine (mg/dL), aspartate aminotransferase/alanine aminotransferase/gamma-glutamyltransferase (IU/L), uric acid (mg/dL). The changes of above markers will be compared between the active group and placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of inflammatory markers</measure>
    <time_frame>Every 12 weeks following randomization, for 24 weeks</time_frame>
    <description>Inflammatory markers such as tumor necrosis factor-alpha (pg/mL) or C-reactive protein (mg/mL) will be checked at baseline, 12 weeks and 24 weeks after randomization. The changes of above markers will be compared between the active group and placebo group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentoxifylline 400mg three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>Pentoxifylline 400mg three times a day</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <other_name>Trental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet three times a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  age &gt;=20 years

          -  spot urine albumin/creatinine ratio &gt; 30mg/g in two consecutive measurements

          -  patients on ACE-inhibitor or ARB as an anti-hypertensive drug

          -  blood pressure &lt;= 150/100 mmHg

          -  HbA1c &lt;10%

        Exclusion Criteria:

          -  taking insulin pentoxifylline, cilostazol, ketas, viagra in 3 months

          -  ischemic heart disease, stroke, malignant disease, severe infection in 6 months

          -  serum creatinine &gt; 2.0mg/dl

          -  severe liver disease or AST, ALT &gt; 3* ULM

          -  taking systemic steroid in 1 month

          -  pregnant or plan to become pregnant during the clinical trial

          -  lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwan-Woo Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Jin Han, MD</last_name>
    <phone>82-31-219-5126</phone>
    <email>hsj@ajou.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Jin Han, md</last_name>
      <phone>82-31-219-5126</phone>
      <email>hsj@ajou.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 27, 2011</lastchanged_date>
  <firstreceived_date>June 22, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Seung Jin Han/ Assistant professor of the Department of Endocrinology and Metabolism</name_title>
    <organization>Ajou University</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>pentoxifylline</keyword>
  <keyword>proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
